Ads
related to: olaparib prostate cancer treatment brachytherapy- Side Effects
Learn More About Potential Side
Effects And Safety Information.
- What Is LYNPARZA?
Learn More About How LYNPARZA
Works And If It's Right For You.
- View FAQs
Find Answers To Frequently
Asked Questions.
- Starting LYNPARZA
Learn More About Eligibility For
LYNPARZA Here At The Official Site.
- Clinical Study Data
Access Clinical Study Data For
LYNPARZA At The Official Site.
- Discover MyLYNPARZA
A Support Program Developed To
Provide Patient Education.
- Side Effects
Search results
Results From The WOW.Com Content Network
Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'. [1]
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor , inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair .
If the cancer has spread beyond the prostate, treatment options change significantly, so most doctors who treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, HIFU, external-beam radiation therapy, brachytherapy, cryosurgery, and surgery are, in general ...
ONCE PROSTATE CANCER is diagnosed, doctors determine what stage the cancer is in and how aggressive it is—and then recommend the most appropriate treatment, says Sunil Kakadia, M.D., a medical ...
Simon Grieveson, assistant director of research at Prostate Cancer UK, said: “For men with advanced prostate cancer, treatment with hormone therapy can be very effective at delaying cancer ...
Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 inhibitor. [31] [32] Started Phase II: Olaparib (developed by AstraZeneca) for breast, ovarian and colorectal cancer. [33] [34] Olaparib TOPARP-A trial for use in advanced prostate cancer (published c. April 21, 2015). [35]
Ads
related to: olaparib prostate cancer treatment brachytherapy